Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMed Pharmaceuticals Inc.INM · Entity 8139 | Director | January 24, 2022 | January 24, 2022 |
| Molecular Templates, Inc.MTEM · Entity 85987 | See remarks | February 15, 2021 | February 17, 2021 |
| NAVIDEA BIOPHARMACEUTICALS, INC.NAVB · Entity 107761 | Director | January 13, 2021 | January 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMed Pharmaceuticals Inc.
Report date January 24, 2022 · Filed January 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Expiration)SEC Table II · derivative / convertible security · Conversion / exercise price $3.82 · Expires 2022-01-24 | Direct | 40,364 |
Reported balance
After 2022-01-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-24 · Other · Disposed 6,061 · Balance 40,364 F1: Converted from the Canadian dollar exercise price of C$4.79 using an exchange rate of C$1.2554 = $US1.00 |
| Employee Stock Option (Expiration)SEC Table II · derivative / convertible security · Conversion / exercise price $3.68 · Expires 2022-01-24 | Direct | 38,849 |
Reported balance
After 2022-01-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-24 · Other · Disposed 1,515 · Balance 38,849 F2: Converted from the Canadian dollar exercise price of C$4.62 using an exchange rate of C$1.2554 = $US1.00 |
| Employee Stock Option (Expiration)SEC Table II · derivative / convertible security · Conversion / exercise price $2.89 · Expires 2022-01-24 | Direct | 16,122 |
Reported balance
After 2022-01-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-01-24 · Other · Disposed 22,727 · Balance 16,122 F3: Converted from the Canadian dollar exercise price of C$3.63 using an exchange rate of C$1.2554 = $US1.00 |
Filing footnotes · ownership attribution and instrument terms
F1: Converted from the Canadian dollar exercise price of C$4.79 using an exchange rate of C$1.2554 = $US1.00
F2: Converted from the Canadian dollar exercise price of C$4.62 using an exchange rate of C$1.2554 = $US1.00
F3: Converted from the Canadian dollar exercise price of C$3.63 using an exchange rate of C$1.2554 = $US1.00
Molecular Templates, Inc.
Report date February 15, 2021 · Filed February 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.05 · Expires 2031-02-15 | Direct | 125,000 |
Reported balance
After 2021-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-15 · Grant · Acquired 125,000 · Balance 125,000 F1: 25% of the shares subject to the option shall vest on February 15, 2022, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option shall vest on February 15, 2022, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over the following 36 months.
NAVIDEA BIOPHARMACEUTICALS, INC.
Report date January 13, 2021 · Filed January 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2021-01-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-01-13 · Grant · Acquired 2,500 · Balance 10,000 F1: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.28 · Expires 2031-01-13 | Direct | 2,500 |
Reported balance
After 2021-01-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-13 · Grant · Acquired 2,500 · Balance 2,500 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mural Oncology plc
Report date December 05, 2025 · Filed December 05, 2025
Section 16 reporting ended · disclosed 2025-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 1
1 source rowRow 1 · 2025-12-05 · Disposition to issuer · Disposed 99,290 · Balance 0 F1: Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time"). F2: Includes the disposition of 77,429 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2033-12-13 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-05 · Disposition to issuer · Disposed 146,452 · Balance 0 F3: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2025-03-02 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-05 · Disposition to issuer · Disposed 65,000 · Balance 0 F3: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time").
F2: Includes the disposition of 77,429 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration.
F3: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2025 Filed Dec 5, 2025 08:43 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerStock Option (right to buy) · Derivative | 65,000 | Not disclosed Strike: $3.43 | Not disclosed |
DisclosureSEC source: 0001193125-25-308739 · ownership.xml · derivative · entry 3 Cutler Adam D. · CIK 0001722673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 65,000 shares Expires 2025-03-02 F3 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F3 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 08:43 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerStock Option (right to buy) · Derivative | 146,452 | Not disclosed Strike: $3.61 | Not disclosed |
DisclosureSEC source: 0001193125-25-308739 · ownership.xml · derivative · entry 2 Cutler Adam D. · CIK 0001722673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 146,452 shares Expires 2033-12-13 F3 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F3 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 08:43 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerOrdinary Shares | 99,290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-308739 · ownership.xml · nonDerivative · entry 1 Cutler Adam D. · CIK 0001722673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time"). F2 · shares: Includes the disposition of 77,429 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration. F1 · price: Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time"). F2 · price: Includes the disposition of 77,429 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration. Read SEC document |
| November 03, 2025 Filed Nov 10, 2025 18:30 UTC | Mural Oncology plc MURA · Entity 72153 | SaleOrdinary Shares | 7,148 | $2.09 | $14,939.32 |
DisclosureSEC source: 0001193125-25-274768 · ownership.xml · nonDerivative · entry 1 Cutler Adam D. · CIK 0001722673 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,290 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 14, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 22, 2023, and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 77,429 unvested restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 16:47 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000950170-25-033761 · ownership.xml · derivative · entry 2 Cutler Adam D. · CIK 0001722673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Ordinary Shares · 65,000 shares Expires 2035-03-02 F3 · derivative.exercise_date: This option was granted on March 3, 2025. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2026 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued services with the Issuer. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 16:47 UTC | Mural Oncology plc MURA · Entity 72153 | GrantOrdinary Shares | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-033761 · ownership.xml · nonDerivative · entry 1 Cutler Adam D. · CIK 0001722673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,438 F1 · shares: Consists of ordinary shares issuable under 35,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2025, subject to the reporting person's continued service with the Issuer. F2 · balance_after: Includes 59,144 unvested restricted stock units. Read SEC document |
| October 31, 2024 Filed Nov 1, 2024 07:04 UTC | Mural Oncology plc MURA · Entity 72153 | SaleOrdinary Shares | 7,421 | $3.41 | $25,305.61 |
DisclosureSEC source: 0000950170-24-119800 · ownership.xml · nonDerivative · entry 1 Cutler Adam D. · CIK 0001722673 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,438 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 14, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 12, 2024, and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.49. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 59,144 unvested restricted stock units. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 16:30 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 146,452 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000950170-23-071115 · ownership.xml · derivative · entry 2 Cutler Adam D. · CIK 0001722673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,452 Underlying: Ordinary Shares · 146,452 shares Expires 2033-12-13 F2 · derivative.exercise_date: This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on October 30, 2024 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 16:30 UTC | Mural Oncology plc MURA · Entity 72153 | GrantOrdinary Shares | 78,859 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-071115 · ownership.xml · nonDerivative · entry 1 Cutler Adam D. · CIK 0001722673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,859 F1 · shares: Consists of ordinary shares issuable under 78,859 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of October 30, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document |
| January 24, 2022 Filed Jan 24, 2022 16:17 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 22,727 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001213900-22-003330 · ownership.xml · derivative · entry 3 Cutler Adam D. · CIK 0001722673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,122 Underlying: Common shares · 22,727 shares Expires 2022-01-24 F3 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$3.63 using an exchange rate of C$1.2554 = $US1.00 Read SEC document |
| January 24, 2022 Filed Jan 24, 2022 16:17 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 1,515 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0001213900-22-003330 · ownership.xml · derivative · entry 2 Cutler Adam D. · CIK 0001722673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,849 Underlying: Common shares · 1,515 shares Expires 2022-01-24 F2 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$4.62 using an exchange rate of C$1.2554 = $US1.00 Read SEC document |
| January 24, 2022 Filed Jan 24, 2022 16:17 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 6,061 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001213900-22-003330 · ownership.xml · derivative · entry 1 Cutler Adam D. · CIK 0001722673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,364 Underlying: Common shares · 6,061 shares Expires 2022-01-24 F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$4.79 using an exchange rate of C$1.2554 = $US1.00 Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 18:00 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001213900-21-068182 · ownership.xml · derivative · entry 1 Cutler Adam D. · CIK 0001722673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,425 Underlying: Common shares · 7,000 shares Expires 2026-12-28 F1 · derivative.exercise_date: The options were granted on 12/29/2021 and will vest 100% on the one year anniversary of the grant date (Dec 29, 2022) or immediately prior to the next AGM, whichever is sooner. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 17:02 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $14.05 | $0.00 |
DisclosureSEC source: 0000899243-21-006915 · doc4.xml · derivative · entry 1 Cutler Adam D. · CIK 0001722673 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-02-15 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 15, 2022, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over the following 36 months. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 16:36 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 2,500 | $0.00 Strike: $2.28 | $2.50 |
DisclosureSEC source: 0001437749-21-000727 · rdgdoc.xml · derivative · entry 2 Cutler Adam D. · CIK 0001722673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2031-01-13 Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 16:36 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock | 2,500 | $0.00 | $2.50 |
DisclosureSEC source: 0001437749-21-000727 · rdgdoc.xml · nonDerivative · entry 1 Cutler Adam D. · CIK 0001722673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · security: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 06:16 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001213900-20-043360 · ownership.xml · derivative · entry 1 Cutler Adam D. · CIK 0001722673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common shares · 7,000 shares Expires 2025-12-15 F1 · derivative.exercise_price: The Canadian exercise price of C$3.85 was converted into U.S. dollars using an exchange rate of C$1.2753 = US$1.00. F2 · derivative.exercise_date: The options were granted on 12/16/2020 and will vest 100% on the one year anniversary of the grant date (Dec 16, 2021) or immediately prior to the next AGM, whichever is sooner. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:59 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0000899243-20-004989 · doc4.xml · derivative · entry 1 Cutler Adam D. · CIK 0001722673 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-02-14 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 14, 2021, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over 36 months. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 16:10 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 2,500 | $0.00 Strike: $1.06 | $2.50 |
DisclosureSEC source: 0001437749-20-002030 · rdgdoc.xml · derivative · entry 2 Cutler Adam D. · CIK 0001722673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires 2030-02-06 Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 16:10 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock | 2,500 | $0.00 | $2.50 |
DisclosureSEC source: 0001437749-20-002030 · rdgdoc.xml · nonDerivative · entry 1 Cutler Adam D. · CIK 0001722673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · security: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 16:32 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0000899243-19-004261 · doc4.xml · derivative · entry 1 Cutler Adam D. · CIK 0001722673 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2029-02-15 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 15, 2020, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over 36 months. Read SEC document |
| February 07, 2019 Filed Feb 12, 2019 16:13 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $0.25 | $50.00 |
DisclosureSEC source: 0001437749-19-002331 · rdgdoc.xml · derivative · entry 2 Cutler Adam D. · CIK 0001722673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-07 Read SEC document |
| February 07, 2019 Filed Feb 12, 2019 16:13 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock | 50,000 | $0.00 | $50.00 |
DisclosureSEC source: 0001437749-19-002331 · rdgdoc.xml · nonDerivative · entry 1 Cutler Adam D. · CIK 0001722673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · security: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 16:26 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $0.75 | $50.00 |
DisclosureSEC source: 0001437749-19-000184 · rdgdoc.xml · derivative · entry 2 Cutler Adam D. · CIK 0001722673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-02 Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 16:26 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock | 50,000 | $0.00 | $50.00 |
DisclosureSEC source: 0001437749-19-000184 · rdgdoc.xml · nonDerivative · entry 1 Cutler Adam D. · CIK 0001722673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · security: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 16:19 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-18-014898 · doc4.xml · derivative · entry 1 Cutler Adam D. · CIK 0001722673 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-05-31 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option shall vest on May 31, 2019, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over 36 months. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 12:37 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0000899243-17-026315 · doc4.xml · derivative · entry 1 Cutler Adam D. · CIK 0001722673 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2027-11-13 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option shall vest on November 13, 2018, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.